Search - tctmd.com

Displaying 41 - 60 of 156

Sort: Relevancy | Date

Data on IVC Filters Sparse but Somewhat Reassuring: Meta-Analysis

News Daily News

Data on IVC Filters Sparse but Somewhat Reassuring: Meta-Analysis

September 19, 2017

Pulmonary Artery Injury More Likely With Real-World Use of CardioMEMS, Analysis Suggests

News Daily News

Pulmonary Artery Injury More Likely With Real-World Use of CardioMEMS, Analysis Suggests

September 19, 2017

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

September 15, 2017

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

News Features

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Michael O'Riordan

September 13, 2017

News Industry News

Medtronic IN.PACT Admiral DCB Global Two Year Data and IN.PACT SFA Four Year Data Presented in VIVA Late Breaking Clinical Trials

September 12, 2017

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

News Conference News VIVA 2017

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

September 11, 2017

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

News Conference News ESC 2017

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

September 07, 2017

Clinical Leaflet Thrombosis After TAVR Tied to Cardiogenic Shock and Death

News Conference News ESC 2017

Leaflet Thrombosis After TAVR Tied to Cardiogenic Shock and Death

Yael L. Maxwell

September 01, 2017

Fentanyl, Ubiquitous in US Cath Labs, Blunts Antiplatelet Drugs in PCI

News Conference News ESC 2017

Fentanyl, Ubiquitous in US Cath Labs, Blunts Antiplatelet Drugs in PCI

September 01, 2017

New Generation Drug Eluting Stents & Bioabsorbable Vascular Scaffolds: Indications, Outcomes, & Complications

Presentation iASSESS 2017

New Generation Drug Eluting Stents & Bioabsorbable Vascular Scaffolds: Indications, Outcomes, & Complications

Presenter: Rajesh V. Swaminathan, Dmitriy N. Feldman

August 30, 2017

Guidelines for the Management of Valvular Heart Disease

Presentation ESC 2017

Guidelines for the Management of Valvular Heart Disease

Presenter: Helmut Baumgartner

August 29, 2017

P2Y12 Inhibitor Pretreatment Questioned in STEMI

News Conference News ESC 2017

P2Y12 Inhibitor Pretreatment Questioned in STEMI

August 29, 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

News Conference News ESC 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

August 27, 2017

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

News Conference News ESC 2017

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

August 27, 2017

STEMI: Treatment Strategies, Drugs And Devices

Presentation iASSESS 2017

STEMI: Treatment Strategies, Drugs And Devices

Presenter: Dharam J. Kumbhani

August 24, 2017

FDA: Class I Recall for Cook’s Thoracic Endovascular Grafts

News Daily News

FDA: Class I Recall for Cook’s Thoracic Endovascular Grafts

Michael O'Riordan

August 17, 2017

News Industry News

Medtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology

August 15, 2017

Reusing the Radial: Repeat Transradial Access Safe and Feasible, Even Within 24 Hours

News Daily News

Reusing the Radial: Repeat Transradial Access Safe and Feasible, Even Within 24 Hours

Michael O'Riordan

August 09, 2017

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

News Daily News

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

Yael L. Maxwell

August 07, 2017

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.